• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Kyverna Therapeutics Inc.

    4/13/26 4:10:04 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KYTX alert in real time by email
    DEFA14A 1 kytx_-_defa14a_proxy_not.htm DEFA14A DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No. )

     

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

     

    KYVERNA THERAPEUTICS, INC.
    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


     

     


     

    img10335942_0.jpg

    Your Vote Counts! KYVERNA THERAPEUTICS, INC. 2026 Annual Meeting Vote by May 26, 2026 11:59 PM ET KYVERNA THERAPEUTICS INC. 5980 HORTON ST, SUITE 550 EMERYVILLE, CA 94608 V88300-P47530 You invested in KYVERNA THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 27, 2026. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 13, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. PV For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* May 27, 2026 11:00 a.m. Pacific Time Virtually at: www.virtualshareholdermeeting.com/KYTX2026 *Please check the meeting materials for any special requirements for meeting attendance.


     

    img10335942_1.jpg

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items 1. The election of two Class II directors to hold office until the Company’s 2029 annual meeting of stockholders. Nominees: 01) Ian Clark 02) Christi Shaw 2. The ratification of the appointment by the Audit Committee of the Company’s Board of Directors of BDO USA, P.C. as the Company’s independent registered public accounting firm and independent auditor for the year ending December 31, 2026. NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment or postponement thereof. Board Recommends For For Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V88301-P47530


    Get the next $KYTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KYTX

    DatePrice TargetRatingAnalyst
    8/20/2025Outperform
    William Blair
    5/27/2025$5.00Neutral → Buy
    H.C. Wainwright
    10/10/2024$13.00Buy
    UBS
    10/9/2024$16.00Buy
    Rodman & Renshaw
    7/3/2024$8.00Neutral
    H.C. Wainwright
    3/4/2024$40.00Overweight
    Morgan Stanley
    3/4/2024$39.00Overweight
    JP Morgan
    3/4/2024$44.00Overweight
    Wells Fargo
    More analyst ratings

    $KYTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Seidenberg Beth C bought $999,998 worth of shares (133,333 units at $7.50) (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    12/22/25 11:43:43 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Westlake Biopartners Opportunity Fund I, L.P. bought $999,998 worth of shares (133,333 units at $7.50) (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    12/22/25 11:42:37 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Kyverna Therapeutics

    William Blair initiated coverage of Kyverna Therapeutics with a rating of Outperform

    8/20/25 8:57:26 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Kyverna Therapeutics from Neutral to Buy and set a new price target of $5.00

    5/27/25 9:06:20 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS initiated coverage on Kyverna Therapeutics with a new price target

    UBS initiated coverage of Kyverna Therapeutics with a rating of Buy and set a new price target of $13.00

    10/10/24 7:37:04 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Kyverna Therapeutics Inc.

    DEFA14A - Kyverna Therapeutics, Inc. (0001994702) (Filer)

    4/13/26 4:10:04 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Kyverna Therapeutics Inc.

    DEF 14A - Kyverna Therapeutics, Inc. (0001994702) (Filer)

    4/13/26 4:02:10 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Kyverna Therapeutics Inc.

    144 - Kyverna Therapeutics, Inc. (0001994702) (Subject)

    4/7/26 4:05:13 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $KYTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026

    EMERYVILLE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced it will host a conference call on Wednesday, April 22, 2026 at 7:00 a.m. ET to discuss the primary analysis from its KYSA-8 registrational trial of miv-cel (mivocabtagene autoleucel, KYV-101) in stiff person syndrome, along with longer-term follow-up data from the KYSA-6 Phase 2 trial in generalized myasthenia gravis (gMG). These data will be shared as oral presentations at the American Academy of Neurology (AAN) Annual Meeting, held April 18-22,

    4/9/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026 Progressing enrollment for FDA-aligned Phase 3 trial in generalized myasthenia gravis (gMG) Positive progressive multiple sclerosis data underscore valuable pipeline-in-a-product opportunity with miv-cel Cash and cash equivalents of $279 million provide expected runway into 2028, funding SPS BLA filing, commercial launch, and Phase 3 gMG trial EMERYVILLE, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell th

    3/26/26 4:02:00 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

    Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS) Oral presentation on updated KYSA-6 Phase 2 data in generalized myasthenia gravis (gMG) EMERYVILLE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced multiple abstracts selected for presentation at the American Academy of Neurology (AAN) Annual Meeting, taking place from April 18-22, 2026, in Chicago, IL. "Our presence at AAN marks an important milestone for Kyverna as we build upon miv-cel's potential to re

    3/5/26 4:21:19 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Grasso Marc was granted 10,000 shares (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    3/17/26 4:30:36 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Biddle Warner Weston was granted 58,000 shares (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    3/17/26 4:30:12 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Gehchan Naji was granted 18,000 shares (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    3/17/26 4:30:10 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    Leadership Updates

    Live Leadership Updates

    View All

    Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

    Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep clinical development and product approval experience to support Kyverna's next phase of growth EMERYVILLE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointments of Sravan K. Emany and Andrew Miller, Ph.D. to its Board of Directors. Mr. Emany will assume the role of Audit Committee Chair, following the transition of Dan Spiegelman from this position, who has stepped d

    2/24/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

    EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Mayo Pujols as its Chief Technology Officer (CTO), effective February 9, 2026. Mr. Pujols brings more than 30 years of technical operations experience to the role with a deep background in leading late-stage and commercial manufacturing for cell and gene therapies. His work spans both large-scale and smaller biopharmaceutical companies with a proven track record of successfully advancing programs across their lifecycles. He succeeds Karen Walker, who is

    2/3/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

    Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) andBLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients with enrollment to initiate by year-end 2025; interim Phase 2 data expected in Q4 2025 Strong cash position to support upcoming milestones EMERYVILLE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the quarter ended June 30, 2025.   "The second quarter was

    8/12/25 4:02:00 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    Financials

    Live finance-specific insights

    View All

    Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026

    EMERYVILLE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced it will host a conference call on Wednesday, April 22, 2026 at 7:00 a.m. ET to discuss the primary analysis from its KYSA-8 registrational trial of miv-cel (mivocabtagene autoleucel, KYV-101) in stiff person syndrome, along with longer-term follow-up data from the KYSA-6 Phase 2 trial in generalized myasthenia gravis (gMG). These data will be shared as oral presentations at the American Academy of Neurology (AAN) Annual Meeting, held April 18-22,

    4/9/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

    Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026  Miv-cel achieved statistically significant clinical benefit across all primary and secondary endpoints, reversing disability and eliminating immunotherapies after a single dose Miv-cel was generally well-tolerated with no high-grade CRS or ICANS observed SPS is a debilitating, progressive autoimmune disease with no FDA-approved therapies Company to host webcast today, December 15, 2025 at 8 am ET EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a c

    12/15/25 6:30:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

    EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will host a live webcast and conference call on Monday, December 15, 2025 at 8:00 am ET to review topline results from the registrational Phase 2 KYSA-8 clinical trial evaluating KYV-101 in stiff person syndrome (SPS). Conference Call Details Participants will need to register at the below-noted URL in order to listen and participate in the call. Once registered, participants will receive a dial-in phone number and unique PIN number which will be needed to join th

    12/14/25 2:30:00 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Kyverna Therapeutics Inc.

    SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)

    11/12/24 7:23:31 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Kyverna Therapeutics Inc.

    SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)

    10/10/24 12:36:27 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Kyverna Therapeutics Inc.

    SC 13D - Kyverna Therapeutics, Inc. (0001994702) (Subject)

    5/3/24 5:57:02 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care